

1 **Validation of a Novel Molecular Assay to the Diagnostic of COVID-19**

2 **Based on Real Time PCR with High Resolution Melting**

3 Beatriz Iandra da Silva Ferreira¹, Natália Lins da Silva Gomes¹, Wagner Luis da Costa

4 Nunes Pimentel Coelho², Vanessa Duarte da Costa³, Vanessa Cristine de Souza

5 Carneiro⁴, Rafael Lopes Kader⁵, Marisa Pimentel Amaro⁵, Lívia Melo Villar³, Fábio

6 Miyajima⁶, Soniza Vieira Alves-Leon⁵, Vanessa Salete de Paula⁴, Luciane Almeida

7 Amado Leon², Otacilio Cruz Moreira^{1,*}

8

9 *¹Real Time PCR Platform RPT09A, Laboratory of Molecular Biology and Endemic*
10 *Diseases, Oswaldo Cruz Institute/ Fiocruz, Rio de Janeiro, Brazil*

11 *²Laboratory of Technological Development in Virology, Oswaldo Cruz Institute/ Fiocruz,*
12 *Rio de Janeiro, Brazil*

13 *³Laboratory of Viral Hepatitis, Oswaldo Cruz Institute/ Fiocruz, Rio de Janeiro, Brazil*

14 *⁴Laboratory of Molecular Virology, Oswaldo Cruz Institute/ Fiocruz, Rio de Janeiro,*
15 *Brazil*

16 *⁵University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro , Rio*
17 *de Janeiro, Brazil*

18 *⁶Oswaldo Cruz Foundation (Fiocruz), Branch Ceará, Eusebio, Brazil*

19

20 *Corresponding author

21 Otacilio Cruz Moreira. Real Time PCR Platform RPT09A, Laboratory of Molecular
22 Biology and Endemic Diseases, Oswaldo Cruz Institute/ Fiocruz, Rio de Janeiro, Brazil.

23 otacilio@ioc.fiocruz.br

24

25 Funding: This work has been founded by INOVA Fiocruz, Coordenação de
26 Aperfeiçoamento de Pessoal de Nível Superior (CAPES - Finance Code 001), CNPq and
27 FAPERJ. LMV, SVAL, VSP, OCM are research Fellows from CNPq and FAPERJ
28 (JCNE and CNE). LAAL is a researcher fellow from FAPERJ (JCNE).

29

30 **Short Running Title: HRM-RTqPCR for COVID-19 molecular diagnostic**

31

32 **ABSTRACT**

33 With the emergence of the Covid-19 pandemic, the world faced an unprecedented need
34 for RT-qPCR-based molecular diagnostic tests, leading to a lack of kits and inputs,
35 especially in developing countries. Hence, the costs for commercial kits and inputs were
36 overrated, stimulating the development of alternative methods to detect SARS-CoV-2 in
37 clinical specimens. The availability of the complete SARS-CoV-2 genome at the
38 beginning of the pandemic facilitated the development of specific primers and
39 standardized laboratory protocols for Covid-19 molecular diagnostic. High-sensitive and
40 cost-effective molecular biology technique based on the Melting Temperature differences
41 between purine and pyrimidine bases can be used to the detection and genotyping of
42 pathogens in clinical specimens. Here, a RT-qPCR assays with High Resolution Melting
43 (HRM-RTqPCR) was developed for different regions of the SARS-CoV-2 genome
44 (RdRp, E and N) and an internal control (human RNase P gene). The assays were
45 validated using synthetic sequences from the viral genome and clinical specimens
46 (nasopharyngeal swabs, serum and saliva) of sixty-five patients with severe or moderate
47 COVID-19 from different states in Brazil, in comparison to a commercial TaqMan RT-
48 qPCR assay, as gold standard. The sensitivity of the HRM-RTqPCR assays targeting N,
49 RdRp and E were 94.12, 98.04 and 92.16%, with 100% specificity to the 3 targets, and

50 diagnostic accuracy of 95.38, 98.46 and 93.85%, respectively. Thus, the HRM-
51 RTqPCR emerges as an alternative and low-cost methodology to increase the molecular
52 diagnostic of patients suspicious for Covid-19, especially in restricted-budget
53 laboratories.

54

55 **KEYWORDS**

56 Covid-19, SARS-CoV-2, Molecular diagnostic, Real Time PCR, High Resolution
57 Melting, Diagnosis

58

59

60 **INTRODUCTION**

61 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-
62 sense single-stranded RNA virus ¹ causative of coronavirus disease 2019 (COVID-19),
63 the airborne-transmitted respiratory illness responsible for the COVID-19 pandemic ².
64 Since its emergence in December 2019, until July 5th 2021, WHO has reported over 183
65 million cases and about 4 million deaths from COVID-19 ³. Compared to the last WHO
66 weekly report, the highest numbers of new cases were reported from India, Brazil, the
67 United States of America, Turkey and Argentina. The majority (~ 80%) of patients have
68 mild symptoms or are asymptomatic, and about 20% of cases may require hospital care
69 because they have difficulty breathing. The mortality rate of COVID-19 has been
70 estimated at around 3% ⁴.

71 The availability of the complete SARS-CoV-2 genome at the beginning of the
72 pandemic facilitated the development of specific primers and standardized laboratory
73 protocols for COVID-19 molecular diagnostic ^{5,6}. The protocols for the firsts real-time
74 RT-qPCR assays, targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp),

75 envelope (E) and nucleocapsid (N), were published on January, 2020 ⁷. After that, WHO
76 produced a technical manual ⁸, where seven in house RT-PCR assays are recommended,
77 developed by CDC-China, Pasteur Institute-France, CDC-USA, NIID-Japan, Charité-
78 Germany, HKU-Hong Kong and NIH-Thailand. All the recommended protocols using
79 TaqMan systems, with TaqMan probes designed for the different regions of the viral
80 genome. Of these, one assay has an internal human control (RNAse P gene, CDC-USA
81 protocol), capable of monitoring the quality of the nucleic acid extraction and validating
82 the true negative result. Based on these reactions, a variety of molecular diagnostic kits
83 were produced and validated in record time. Even so, the production of these kits could
84 be not enough to cover the immense demand for diagnostics worldwide, and the costs are
85 generally overpriced. Therefore, it should be considered to invest in low-cost alternative
86 technologies, to assist the diagnosis of COVID-19 in a less dependent way on imported
87 products and inputs.

88 The reverse transcription polymerase chain reaction real time assays with High
89 Resolution Melting (HRM-RTqPCR) analysis is a high-sensitive and cost-effective
90 molecular biology technique based on the Melting Temperatures (T_m) difference between
91 purine and pyrimidine bases that can be used for the detection of mutations,
92 polymorphisms and epigenetic differences (quantification of methylation status of CpG
93 sites) in double-stranded DNA samples ⁹. HRM-qPCR based methodologies have been
94 reported for the detection and genotyping of different pathogens, such as virus, bacteria
95 and protozoa in clinical samples ¹⁰⁻¹³. Due to the possibility of PCR products
96 differentiation by the T_m at the melting curves with high resolution, it is possible to
97 combine different sets of primers, specific for different pathogens or more than one target
98 in the same pathogen and/or an internal control. HRM-RTqPCR master mix contains a
99 fluorophore instead of fluorescent probes, for this reason it becomes less expensive than

100 TaqMan assays or DNA sequencing to the molecular diagnostic or pathogens genotyping
101 from clinical samples.

102 In this study, real-time RT-PCR assays with High Resolution Melting were
103 developed for different regions of the SARS-CoV-2 genome (RdRp, E and N) and an
104 internal control (human RNase P gene). The assays were standardized and validated
105 using synthetic sequences from the viral genome and clinical specimens (nasopharyngeal
106 swabs, serum and saliva) of patients with clinical suspicion of COVID-19 from different
107 states of Brazil, in comparison to TaqMan RT-qPCR assays, as gold standard. Therefore,
108 we aimed to obtain an sensitive and specific assay to COVID-19 diagnosis as an
109 alternative to TaqMan assay to overcome high costs and the limited supplies that might
110 delay accurate diagnosis.

111

112 **MATERIAL AND METHODS**

113 **Ethics Statement**

114 This study was approved by the ethical committee of Clementino Fraga Filho
115 University Hospital, from Federal University of Rio de Janeiro (UFRJ), CAAE number
116 31240120.0.0000.5257. All patients or a member of their families signed the consent
117 form.

118

119 **Clinical samples**

120 In this study, a panel of 42 nasopharyngeal swab, 12 serum and 11 saliva samples
121 from 65 patients with severe or moderate COVID-19, admitted during the acute phase of
122 the infection, were included. Forty-Five and Twenty patients were from the Rio de
123 Janeiro state and Ceará state, respectively. Of these samples, 51 were positive and 14
124 were negative to the molecular detection of SARS-CoV-2 for the RT-qPCR TaqMan

125 assay targeting the N region of viral genome. The inclusion criteria was the presence of
126 clinical symptoms compatible with COVID-19 during the admittance and presented at
127 least one SARS-COV-2 laboratorial analysis. Patients under 18 years old, pregnant
128 women and with cancer were excluded from this study.

129 To the nasopharyngeal samples collection, swab was inserted through the nostril
130 with a rotation movement until the nasopharynx was reached, and the sample was
131 obtained by rotating the swab gently for 2-3 seconds. Then, the swab was placed into a 5
132 ml tube containing 3 ml viral transport medium (VTM). After transportation to the
133 laboratory, tubes containing the swabs were vortexed vigorously, VTM was transferred
134 to 1.5mL tubes and stored at -80°C until RNA extraction.

135 To the saliva samples collection, patients were asked to self-collect the saliva in a
136 sterile dry tube, closing the lid after placing the saliva in it. The staff cleaned the outside
137 of the tube with 1/10 diluted bleach-impregnated cloth, after taking the container while
138 wearing gloves. After taking both samples, they were delivered to the laboratory inside
139 the triple transport system.

140 To the serum samples collection, around five milliliters of blood were harvested
141 in a BD Vacutainer® Plus Plastic Serum tube and remained resting for 30 min at room
142 temperature, to generate the clot from blood cells and the serum phase. After that, tubes
143 were centrifuged at 1,000 x g for 10 minutes at 4 °C and serum was collected and stored
144 at -80°C until use.

145

146 **Viral RNA extraction and cDNA synthesis**

147 RNA was extracted from 140 µL of nasopharyngeal swab VTM (Virus Transport
148 Media), serum or saliva, using the QIAamp Viral RNA Mini Kit (Qiagen, USA),

149 according to the manufacturer's instructions. At the final step of the protocol, RNA was
150 eluted at 60 μ L of AVE Buffer and stored at -80°C until use.

151 To the two-steps HRM-RTqPCR assays, reverse transcription was performed
152 from 5 μ L RNA using the SuperScript III First-Strand Synthesis System (Invitrogen,
153 USA), according to manufacturer's instructions, using 1 μ L of the equimolar mixture of
154 2019-nCoV_N2-R, nCoV 1_IP4-14146Rv, E_Sarbeco_R2 and RP-R primers at 2 μ M
155 each.

156

157 **Real Time RT-PCR with TaqMan assays**

158 All patient samples were analyzed for SARS-Cov-2 N2 and human RNaseP
159 targets using a commercial One-Step RTqPCR TaqMan kit, 2019-nCov CDC RUO Kit
160 (IDT DNA, USA. Cat. No. 10006625), according to manufacturer's instructions. RT-
161 qPCR was carried out in 10 μ L reaction containing 2 μ L RNA, 5 μ L Promega Go-Taq
162 Probe-1-Step-RT-qPCR System [2X], 0.2 μ L GoScript RT mix for 1-step RT-qPCR, 0.75
163 μ L Mix Primer-Probe FAM/BHQ (N2 or RNase P) TaqMan, 0.25 μ L CXR Reference
164 Dye and 1.8 μ L ultrapure water. Real-time PCRs were carried out on Applied Biosystems
165 Quantstudio 3 Real-Time PCR System (ThermoFisher, USA) using the following cycling
166 conditions: 15 min at 50°C , 10 min at 95°C , followed by 40 cycles of 15 sec at 95°C and
167 60 sec at 55°C . Fluorescence was collected after each cycle at the annealing/extension
168 step. All samples were run in duplicate and threshold was set at 0.02 for analysis.

169

170 **Primers selection**

171 To select the primers for HRM-RTqPCR assays (Table 1), sequences were
172 analyzed for Tm, hairpin, self-dimer and hetero-dimer formation using the OligoAnalyzer
173 Tool (Integrated DNA Technologies, USA), available at

174 <https://www.idtdna.com/calc/analyzer>. In addition, primers were also evaluated *in silico*
175 for their specificity. A primer-BLAST search
176 (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>) using the sequences of each primer
177 pair and allowing up to 4 mismatches (none in the 3' end) in the complete set of the
178 NCBI database (non-redundant sequences) resulted only in SARS-CoV-2 and RNase P
179 gene related-sequences.

180

181 **Real Time RT-PCR with High Resolution Melting**

182 To the HRM-RTqPCR assays, all cDNA were analyzed for SARS-CoV-2 N2,
183 RdRp and E target. As an internal control, the human RNase P target was used. The
184 assays were carried out in a final volume of 10 μ L, containing 2 μ L [5X] Hot Firepol
185 Evagreen HRM Mix (No ROX), 200 nM 2019-nCoV_N2 F and 2019-nCoV_N2 R
186 primers; or 300 nM nCoV_IP4-14059Fw and nCoV_IP4-14059 Rv primers; or 200 nM
187 E_Sarbeco_F1 and 300 nM E_Sarbeco_R2 primers (Table 1); or 300 nM RP-F and 300
188 nM RP-R primers; 2 μ L cDNA and ultrapure water to reach 10 μ L. Real-time PCRs were
189 carried out on Applied Biosystems Quantstudio 3 Real-Time PCR System
190 (ThermoFisher, USA) using the following cycling conditions: 10 min at 95 °C, followed
191 by 40 cycles of 15 sec at 95°C and 60 sec at 58 °C (N and RdRp targets) or 60 °C (E and
192 RNase P targets), where fluorescence was collected after each cycle. Melt curve stage
193 conditions were: 10 sec at 95°C, 60 sec at 60 °C, 15 sec at 95 °C (where fluorescence was
194 collected at 0.025 °C/s rate) and 15 sec at 60 °C. Threshold was established and set at
195 10,000 for analysis.

196

197 **Controls and Analysis**

198 In each assay, positive and negative controls were used, as follows: low positive
199 control (synthetic template of single-strand DNA containing N, RdRp and E genes of
200 SARS-CoV-2 (GenBank NC_045512.2), at 200 copies/ μ L), very low positive control
201 (synthetic template of single-strand DNA containing N, RdRp and E genes of SARS-
202 CoV-2 (GenBank NC_045512.2), at 20 copies/ μ L), and negative template control. In
203 addition, one negative control of RNA extraction was added at each extraction batch,
204 using ultrapure water instead samples. To observe the amplification plots and Ct values,
205 results were analyzed using the QuantStudio Design and Analysis Software v1.5.1
206 (Applied Biosystems, USA). High Resolution Melt Software v.3.2 (Applied Biosystems,
207 USA) was used to distinguish the high resolution melting curves and obtain Melting
208 Temperature (T_m) values.

209

210 **Analytical Validation**

211 The analytical validation (Dinamic Extension, Precision, Reproducibility) assays
212 were performed using synthetic single strand DNA molecules containing the N, RdRp
213 and E regions of SARS-CoV-2 from the Severe acute respiratory syndrome coronavirus
214 2 isolate Wuhan-Hu-1 (GenBank NC_045512.2). To the linearity assay, a 1:10 serial
215 dilution of the synthetic DNA was performed from 10^6 to 1 copies/ μ L in TE buffer. To
216 the precision assay, three concentrations of the synthetic SARS-CoV-2 templates were
217 used (12, 10 and 8 copies/ μ L). Forty technical replicates were assayed in each
218 concentration to the same operator in the same day, and the results were compared. To
219 the Reproducibility assay, the same three concentrations of the synthetic sequences, at 12,
220 10 and 8 copies/ μ L, were also used. The amplification was performed in 40 technical
221 replicates for each template concentration, divided in two consecutive days, by the same
222 operator.

223

224 **Statistical analysis**

225 All experiments were performed at least in two technical replicates. Data
226 distribution was evaluated by the Shapiro-Wilk normality test. Student's t-test or Mann-
227 Whitney Rank Sum test was used to analyze the statistical significance of the observed
228 differences (according to the parametric or nonparametric distribution of the values,
229 respectively) with SigmaPlot for Windows version 12.0 (Systat Software, Inc). Values of
230 sensitivity, specificity, PPV, NPV, Diagnostic accuracy and Cohen's kappa coefficient
231 were calculated using the Open Source Epidemiologic Statistics for Public Health
232 (OpenEpi software V3.01), available at www.openepi.com. Results were expressed as
233 means and standard deviations, and differences were considered significant if $p < 0.05$.

234

235 **RESULTS**

236 **Primers selection**

237 To select the appropriate primers to develop the HRM-RTqPCR assays, the primers
238 designed for COVID-19 molecular diagnostic described by WHO⁸ were evaluated based
239 on the T_m similarity between primer pairs, low hairpin, self-dimer and hetero-dimer
240 formation tendency, small amplicon size (below 120 bp), and PCR efficiency. Therefore,
241 they were selected the primers 2019-nCoV_N2-F and 2019-nCoV_N2-R (CDC, USA),
242 nCoV_IP4-14059Fw and nCoV 1_IP4-14146Rv (Institut Pasteur, France),
243 E_Sarbeco_F1 and E_Sarbeco_R2 (Charité, Germany) and RP-F and RP-R (CDC, USA)
244 targeting N, RdRp and E regions of the SARS-Cov-2 genome and Human RNase P gene,
245 respectively (Table 1). Those primers were selected based on the T_m similarity between
246 primer pairs, low hairpin, self-dimer and hetero-dimer formation tendency and small
247 amplicon size (below 120 bp).

248

249 **Analytical Validation of HRM-RTqPCR assays**

250 After standardization, HRM-qPCR assays were initially validated using synthetic DNA
251 sequences of SARS-CoV-2 (GenBank NC_045512.2). A single and sharp peak at the
252 derivative HRM curve was generated to each target, with T_m 80.8, 83.5, 77.6 and 86°C
253 to N, RdRp, E and RNase P, respectively (Table 1 and Fig. 1A). Due to the distribution
254 of the peaks, the pre-melt and post-melt regions of HRM were established before 72 and
255 after 90.8 °C, respectively (Fig. 1A). Thus, the normalized HRM graph showed four
256 distinguished curves, capable to be analyzed in conjunct (Fig. 1B). The analysis of the
257 standard curves produced by the serial dilution of the synthetic controls showed a
258 dynamic range between 10^6 and 10 copies/ μ L to the N, RdRp and E SARS-CoV-2 targets
259 (Table 1 and Fig. 1C). The PCR efficiencies were between 88.3 and 109.7%, leading to
260 the possibility of viral load quantification by HRM-RTqPCR with accuracy, with low Ct
261 difference between the three targets. In addition, it was possible to observe the same
262 approximate limit of detection (LOD) – the lowest concentration detected in the linearity
263 assay, around 10 copies/ μ L, to the three targets in SARS-CoV-2.

264 When clinical samples (RNA extracted from nasopharyngeal swab, serum or
265 saliva) were evaluated, the same normalized HRM curve profile was observed in
266 comparison to the synthetic controls, with few differences between samples (Fig. 1D, 1E
267 and 1F to the N, RdRp and E targets, respectively), validating the use of the HRM curves
268 to confirm the product of amplification of SARS-CoV-2 in the positive samples.

269 Following analytical validation, the precision of HRM-RTqPCR assays was
270 evaluated. For that, three concentrations around the estimated LOD (10 copies/ μ L) were
271 selected: 12, 10 and 8 copies/ μ L of the synthetic SARS-CoV-2 templates. For N, RdRp
272 and E targets, forty technical replicates were assayed in each concentration, and the results

273 were compared (Table 2). To the N target, 100% of positive amplification was observed
274 to the three concentrations, with Ct means (\pm Standard Deviation) of 29.80 ± 0.51 ,
275 30.44 ± 0.43 and 30.57 ± 0.53 , and coefficients of variation of 1.73%, 1.40% and 1.74%,
276 respectively. To the RdRp target, 97.5% of positive amplification was observed to the
277 three concentrations, with Ct means of 30.85 ± 0.51 , 30.77 ± 0.99 and 30.70 ± 0.83 , and
278 coefficients of variation of 3.74%, 3.20% and 2.71%, respectively. Finally, to the E target,
279 97.5%, 87.5% and 97.5% of positive amplification were observed to 12, 10 and 8
280 copies/ μ L, with Ct means of 28.87 ± 0.46 , 28.41 ± 0.36 and 28.70 ± 1.05 , respectively. To
281 this target, the coefficients of variation were 1.60%, 1.27% and 3.65%, respectively. Even
282 with slight differences, the coefficient of variation to all targets and concentrations tested
283 were lower than 5.0%, showing the high precision of the assays.

284 The reproducibility of the HRM-RTqPCR assays on the detection of SARS-CoV-
285 2 was also evaluated through the amplification (Ct values) of the synthetic sequences at 12,
286 10 and 8 copies/ μ L. The amplification was performed in 40 technical replicates for each
287 template concentration, divided in two consecutive days, by the same operator. The box
288 plot in Fig. 2 shows the distribution of Ct values in the technical replicates and between
289 the two days of analysis, for each target. To the N target, the medians of Ct values for
290 days one and two, at 12 copies/ μ L, were respectively 29.57 and 29.89. At 10 copies/ μ L,
291 the medians were 30.46 and 30.34 and, at 8 copies/ μ L, the medians were 30.39 and 30.63,
292 respectively. To the RdRp target, the medians of Ct values for days 1 and 2, at 12
293 copies/ μ L, were respectively 31.49 and 29.92. At 10 copies/ μ L, the medians were 30.42
294 and 30.84 and, at 8 copies/ μ L, the medians were 30.40 and 30.78, respectively. To the E
295 target, the medians of Ct values for days one and two, at 12 copies/ μ L, were respectively
296 28.58 and 28.93. At 10 copies/ μ L, the medians were 28.25 and 28.62 and, at 8 copies/ μ L,
297 the medians were 28.42 and 28.61, respectively. It was possible to observe a little

298 dispersion of Ct values in the replicates, and a small number of outliers in all
299 concentrations tested. In addition, no significant difference was observed in Ct values
300 between day 1 and day 2 for all the targets, which means a good reproducibility of the
301 HRM-qPCR assays.

302

303 **Clinical validation of HRM-RTqPCR assays**

304 In order to assess the quality of the samples and RNA extraction, differentiating
305 true- and false-negative results, the amplification of the internal control human RNase P
306 was monitored in all clinical specimens, to the TaqMan RT-qPCR and HRM-RTqPCR
307 assays, in parallel to the detection of SARS-CoV-2 (Fig. 3A). Even considering some
308 outliers, no significant difference was observed in Ct values between TaqMan and HRM
309 assays ($p=0.634$), showing the improved amplification of the RNase P target in the HRM
310 assay developed in this study. In addition, all the samples presented RNase P $Ct < 35$,
311 except samples 54 ($Ct\ 35.203$ – serum) and 65 ($Ct\ 36.440$ – saliva) (Table S1). When the
312 Ct values were compared between the type of clinical samples (swab, serum or saliva –
313 Fig. 3B), significantly higher Ct values were observed to the serum samples, in
314 comparison to swab or saliva. No significant difference was observed between swab and
315 saliva samples ($p=1.000$) (Fig. 3B), indicating a similar RNA quantity and recovery
316 between both type of samples.

317 After assessing the quality of the samples through the human RNase P internal
318 control amplification, the clinical validation on the SARS-CoV-2 detection was
319 performed with samples from 65 patients from the Rio de Janeiro and Ceará States in
320 Brazil (42 swab, 12 serum and 11 saliva samples). The TaqMan assay targeting the N
321 region of SARS-CoV-2 was considered the gold standard for the parameter's evaluation.
322 From the 65 samples, 51 were positive and 14 negative by the gold standard. The

323 sensitivity of the HRM RTqPCR assays targeting N, RdRp and E were, respectively,
324 94.12, 98.04 and 92.16% (Table 3). The specificities were 100% to the 3 targets. The
325 Positive Predictive Values were 100% to all targets, and the Negative Predictive Values
326 were 82.35, 93.33 and 77.18% to the N, RdRp and E targets, respectively. In addition, the
327 diagnostic accuracy was 95.38, 98.46 and 93.85%, respectively. To estimate the
328 agreement between HRM x TaqMan assays, the Cohen kappa coefficient was calculated.
329 It was observed the coefficients of 0.87, 0.96 and 0.84 to the N, RdRp and E targets,
330 respectively. In general, the three HRM assays presented good clinical validation
331 parameters, with elevated diagnostic accuracy, above 90%, in comparison to the TaqMan
332 assay, including one positive amplification in serum samples (from 12) and 8 positive
333 amplification in saliva samples (from 11). In conjunct, the HRM assay targeting RdRp
334 was the one with the best clinical performance, with the most elevated sensitivity,
335 specificity, PPV, NPV, accuracy and Cohen's kappa coefficient levels.

336 Finally, the pairwise comparison of Ct values between RT-qPCR TaqMan and
337 HRM-RTqPCR assays to the N, RdRp and E targets in SARS-CoV-2 was performed
338 using a Bland-Altman Plot (Fig. 4). The comparison was done to the TaqMan N x HRM
339 N assays (Fig. 4A), TaqMan N x HRM RdRp assays (Fig. 4B) and TaqMan N x HRM E
340 assays (Fig. 4C). The Bland-Altman Plot is a method to evaluate the agreement between
341 two different assays, allowing the identification of any systematic difference between the
342 measurements (i.e., fixed bias) or possible outliers. To the comparison between TaqMan
343 and HRM to the N target for the 65 specimens analyzed, a bias of 0.56 and only three
344 outliers (with Ct difference outside de $\text{mean} \pm 1.96$ Standard Deviation) were observed
345 (Fig. 4A). When the comparison was performed between the TaqMan N and HRM RdRp
346 assays, a bias of -1.71 with only three outliers were observed (Fig. 4B). Lastly, when the
347 comparison was between TaqMan N and HRM E assays, a bias of -0.89 with also three

348 outliers were observed. In all comparisons, those parameters represent a very good
349 agreement between the assays, which resulted in a performance of the HRM-RTqPCR
350 similar to the gold standard TaqMan RTqPCR assay.

351

352 **DISCUSSION**

353 With the emergence of the Covid-19 pandemic, the world faced an unprecedented
354 need for RT-qPCR-based molecular diagnostic tests, leading to a lack of kits and inputs,
355 especially in developing countries. In March 2020, to increase the reach of Covid-19
356 molecular diagnostic, WHO produced a technical manual recommending seven in-house
357 RT-qPCR assays, developed and validated by recognized research centers worldwide ⁸.
358 This manual helped institutions of support, such as universities and small research groups,
359 to also contribute to the Covid-19 frontline. However, with the high demand for molecular
360 diagnostic tests, the costs for commercial kits and inputs were overrated, stimulating the
361 development of alternative methods to detect SARS-CoV-2 in clinical specimens.
362 Therefore, the main goal of this study was to develop a low-cost in-house HRM-RTqPCR
363 assay, using alternative and more economical inputs, to increase the testing of patients
364 suspicious for Covid-19, especially in restricted-budget laboratories.

365 HRM is a method developed in 2002 by the University of Utah (USA) and Idaho
366 Technology (USA) for DNA sequence analysis ⁹. As the easiest DNA genotyping method,
367 mutation screening and sequence matching, the number of studies reporting the use of
368 HRM is continuous growth. The HRM cost-advantage results from the easiness of the
369 method: beyond the PCR reagents, it is required only a saturating DNA dye, that costs
370 much less than a fluorescent probe. Although genotyping corresponds to the main HRM
371 application, the use of this methodology for the simultaneous molecular diagnostic and
372 genotyping of pathogens, including the first coronavirus, is also promising ^{10, 13-15}.

373 Based on the TaqMan in-house assays, we first evaluated all the primers
374 sequences *in silico*, selecting three primers pairs targeting the N, RdRp and E regions of
375 SARS-CoV-2 genome. As the main objective of this study was to develop HRM-
376 RTqPCR assays to the molecular detection of the virus, regardless the mutations
377 accumulated by the variants of concern, it was important to select the most stable genes
378 to the diagnostic assays, to avoid the presence of insertions, deletions or SNPs that can
379 lead to primer mismatches or differences in the shape of the HRM curves, used to certify
380 the specificity of the RT-qPCR amplifications.

381 In this study, the analytical validation of HRM-qPCR assays was performed based
382 on international guidelines ¹⁶, using synthetic sequences of SARS-CoV-2. Our first results
383 showed a sharp peak for each SARS-CoV-2 target and human RNase P at the derivative
384 melting curves, with Tms differing at least 2.5°C between the targets. Although it was
385 not explored in this study, the Tm differences open a possibility for multiplexing these
386 assays, lowering even more the costs. However, in order to reach the best condition, it
387 could be necessary to standardize the assays in multiplex, modifying the concentrations
388 of primers and master mix reagents, as MgCl₂ and dNTP, which is limited in the
389 commercial HRM master mixes available.

390 The dynamic range of the HRM-RTqPCR assays observed to the 3 SARS-CoV-2
391 targets presented 5 logs and approximated LOD of 10 copies/μL, with PCR efficiencies
392 between 88.3% and 109.7%. The shape of the normalized HRM curves was very similar
393 between all positive patient samples and the synthetic templates, used as reference. In
394 fact, the clinical specificity observed to those three HRM-RTqPCR assays were 100%,
395 which corroborates the similar shape and solely peak of each HRM curve. If a mutation
396 occurred in the N, RdRp and E regions amplified by the primers used, it would be possible
397 to observe a difference in the normalized HRM curves, which would be detected by the

398 HRM software and reported as a variation. In this study, by the 145 positive HRM-
399 RTqPCR results, the stability of the N, RdRp and E regions in the SARS-CoV-2 genome
400 was demonstrated.

401 One of the main concerns in HRM-based assays regards its repeatability and
402 reproducibility. Following the Clinical and Laboratory Standards Institute (CLSI)
403 document EP12-A2 for qualitative tests ¹⁷, we performed a replication experiment to
404 evaluate precision of the three HRM-RTqPCR assays to SARS-CoV-2 using three low
405 concentrations of the synthetic templates, around the estimated LOD. The parameters of
406 precision were evaluated from the Ct values observed in each assay. The three assays
407 presented a high precision, estimated by the small coefficient of variation observed, below
408 2%, except for the E target assay at 8 copies/ μ L (3.65%). Even for this target, the CV was
409 below 15%, as recommended ¹⁸. To evaluate reproducibility, the three assays were
410 performed in twenty technical replicates for each concentration around the LOD, by the
411 same operator in two consecutive days, totalizing forty replicates. The Ct values were
412 compared between day one and day two for each target, but no statistical difference was
413 observed (Fig. 2), assuring the good reproducibility of the method.

414 The clinical validation of the HRM-RTqPCR assays was performed with 65
415 samples, mostly nasopharyngeal swabs, but also saliva and serum. The human RNase P
416 gene was used as internal control, for both TaqMan and HRM assays. No statistical
417 difference was observed in the RNase P Ct values between TaqMan and HRM assays,
418 which suggest that the sensitivity for this target amplification was similar between the
419 two methods. Nevertheless, when the Ct values were compared between the different type
420 of samples in the HRM-RTqPCR assays, serum samples presented the higher RNase P
421 Ct values, significantly different from nasopharyngeal swabs and saliva. As expected,
422 during the serum preparation, cells containing mRNA, including the RNase P transcript,

423 keep trapped at the clot. This probably result in a lower detection of this human target in
424 serum samples. Regardless, previous studies already described detection of SARS-CoV-
425 2 in serum ¹⁹, which could be associated with increase mortality risk in hospitalized
426 COVID-19 patients ²⁰.

427 As reported, the three HRM assays validated herein presented high sensitivity
428 (from 92.16% to 98,04%) and specificity (all 100%). Regardless the kind of sample, a
429 very good concordance could be observed with the TaqMan assay, except for three
430 nasopharyngeal swab and one serum samples (Table S1). From those, only one sample
431 was positive to TaqMan but negative to the three HRM assays. This sample presented
432 Ct=37.02±0.07, the highest Ct observed to the TaqMan assays in this study. In addition,
433 the other three samples also presented high Ct values to the TaqMan assay, higher than
434 34. It is important to mention that most patients suspicious for Covid-19 that search the
435 health systems are in the acute phase of the disease, in which a high viral load is observed
436 and the molecular diagnostic is recommended ²¹. In addition, the Ct values variability
437 among the the samples observed in this study can, perhaps, be justified due the fact that
438 the samples analyzed were not collected during similar time intervals between the
439 symptoms onset and collection. Noteworthy, the HRM-RTqPCR assays validated in this
440 study presented elevated sensitivity to the detection of the SARS-CoV-2 genome even
441 considering the samples presenting lower viral loads, observed through high Ct values in
442 the gold standard assay.

443 Finally, the agreement between TaqMan and HRM assays was evaluated by the
444 Bland-Altman plot analysis with the pairwise comparison of Ct values. The HRM assays
445 to three targets in the virus were compared to the TaqMan assay targeting the N region.
446 The three HRM assays present a high agreement with the gold standard, with biases very
447 close to zero and only three outliers (out of ±1.96 Standard Deviation) in each

448 comparison. It means that the Ct values are very similar performing the TaqMan or HRM
449 assays, even for different targets in the SARS-CoV-2 genome. Considering that each
450 region presents only one copy at the virus genome, and the PCR efficiencies were very
451 similar among the targets and close to 100%, it is plausible to expect similar Ct values to
452 all the targets and the TaqMan assay. Taken together, our results open a new venue of
453 low-cost alternatives for the molecular diagnostic of Covid-19 in different kind of
454 samples, with promising application to the SARS-Cov-2 genotyping and identification of
455 the variants of concern, after the adaptation of the current assays to the S region in the
456 viral genome. Of note, the estimated cost for the HRM-RTqPCR assay is significantly
457 lower than a commercial kit for the molecular diagnostic of Covid-19 based on the
458 TaqMan system, and much lower than a DNA sequencing to identify the SARS-CoV-2
459 variants, which could represent a considerable economy for the public health systems.

460

461 *Conclusion*

462 The HRM-RTqPCR assays targeting the N, RdRp and E regions of the SARS-
463 CoV-2 presented high sensitivity and specificity to the molecular diagnostic of Covid-19
464 from nasopharyngeal swabs, serum or saliva samples, being a low cost alternative to the
465 TaqMan assays current available and a promising methodology to the development of
466 new assays to the discrimination of the SARS-CoV-2 variants of concern.

467

468 **ACKNOWLEDGMENTS**

469 Authors would like to thank to all the clinical staff involved in patient assistance
470 and sample harvesting, as well as the technicians from the Technological Platforms from
471 Fiocruz for the support.

472

473 **AUTHOR CONTRIBUTIONS**

474 OM and LL are the guarantors of this work and, as such, had full access to all of the data
475 in the study and take responsibility for the integrity of the data and accuracy of data
476 analysis. OM conceived and designed the study. SVAL take the responsibility of write
477 and submit the approved COVID-19 Biomarker Project, RK and MA admitted and
478 followed-up part of the Covid-19 patients, obtained samples for the qPCR assays; OM
479 Analyzed the oligonucleotides and designed the synthetic templates; WC, VDC, LMV
480 VC) carried out the RNA extraction from nasopharyngeal swabs, serum and saliva
481 samples; BF and NG carried out experiments related to standardization and validation of
482 the HRM-RTqPCR assays; LMV, FM, VP and LL supervised analysis and interpretation
483 of results and revised the manuscript. OM wrote the original draft and the revised
484 manuscript. OM and LL gave financial support to the work. All authors approved the final
485 version of the manuscript.

486

487 **REFERENCES**

- 488 1. Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al.: The
489 Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2
490 Infections. *Journal of Neuroimmune Pharmacology* 2020, 15 (3): 359–386.
- 491 2. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et
492 al.: The species Severe acute respiratory syndrome-related coronavirus:
493 classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology* 2020,
494 5 (4): 536–544.
- 495 3. WHO. COVID-19 Weekly Epidemiological Update (May 11th, 2021). World
496 Health Organization 2021. Available at:

- 497 [https://www.who.int/publications/m/item/weekly-operational-update-on-covid-](https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19)
498 [19](https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19). Accessed at 5-july-2021
- 499 4. Morbidity and Mortality Weekly Report (MMWR). Coronavirus disease 2019 in
500 children – United States 2020, 69 (14):422-426.
- 501 5. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N,
502 Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J,
503 Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang 441 D, Xu W,
504 Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W: Genomic characterization
505 and epidemiology of 2019 novel coronavirus: implications for virus origins and
506 receptor binding. Lancet 2020, pii: S0140- 6736(20)30251-8.
- 507 6. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH,
508 Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes
509 EC, Zhang YZ: A new coronavirus associated with human respiratory disease in
510 China. Nature 2020, 579: 265–269.
- 511 7. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T,
512 Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer
513 B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M,
514 Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C: Detection of 2019
515 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020, 25.
- 516 8. WHO 2020. WHO in house protocols for COVID-19. World Health Organization.
517 Available at: [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/whoinhouseassays.pdf?sfvrsn=de3a76aa_2)
518 [source/coronaviruse/whoinhouseassays.pdf?sfvrsn=de3a76aa_2](https://www.who.int/docs/default-source/coronaviruse/whoinhouseassays.pdf?sfvrsn=de3a76aa_2). Accessed at: 26-
519 april-2020.

- 520 9. Reed GH, Kent JO, Wittwer CT: High-resolution DNA melting analysis for
521 simple and efficient molecular diagnostics. *Pharmacogenomics* 2007, 8(6): 597-
522 608.
- 523 10. Hewson KA, Browning GF, Devlin JM, Ignjatovic J, Noormohammadi AH:
524 Application of high-resolution melt curve analysis for classification of infectious
525 bronchitis viruses in field specimens. *Aust Vet J* 2010, 88(10):408-13.
- 526 11. TONG SYC, GIFFARD PM: Microbiological Applications of High-Resolution
527 Melting Analysis. *Journal of Clinical Microbiology* 2012, 50(11): 3418–3421.
- 528 12. HONG YJ et al.: Detection of herpes simplex and varicella-zoster virus in clinical
529 specimens by multiplex real-time PCR and melting curve analysis. *BioMed*
530 *Research International* 2014, 2014: 261947.
- 531 13. Sun Y, Cheng Y, Lin P, Zhang H, Yi L, Tong M, Cao Z, Li S, Cheng S, Wang J:
532 Simultaneous detection and differentiation of canine parvovirus and feline
533 parvovirus by high resolution melting analysis. *BMC Vet Res* 2019, 15(1):141.
- 534 14. Hewson, K., Noormohammadi, A.H., Devlin, J.M. *et al.*: Rapid detection and
535 non-subjective characterisation of infectious bronchitis virus isolates using high-
536 resolution melt curve analysis and a mathematical model. *Arch Virol* 2009,
537 154: 649.
- 538 15. Chua, K. H. et al.: Development of High Resolution Melting Analysis for the
539 Diagnosis of Human Malaria. *Sci Rep* 2015, 5: 15671.
- 540 16. Burd EM: Validation of laboratory-developed molecular assays for infectious
541 diseases. *Clin Microbiol Rev* 2010, 23(3): 550-76.
- 542 17. CLSI/NCCLS 2008: User protocol for evaluation of qualitative test performance.
543 Approved guideline, 2nd ed. CLSI document EP12-A2. Clinical and Laboratory
544 Standards Institute 2008., Wayne, PA.

- 545 18. Food and Drug Administration 2001: FDA guidance for industry: bioanalytical
546 method validation. Center for Drug Evaluation and Research, U.S. Department of
547 Health and Human Services, Rockville, MD.
- 548 19. Kima JM, Kima HM, Leea EJ, Joa HJ, Yoona Y, Leea NJ, Sona J, Leea YJ, Kima
549 MS, Leea YP, Chaea SJ, Parka KR, Choa SR, Parka S, Kima SJ, Wanga E, Wooa
550 SH, Lima A, Parka SJ, Janga JH, Chunga YS, Chinb BS, Leec JS, Limd D, Hana
551 MG, Yoo CK: Detection and Isolation of SARS-CoV-2 in Serum, Urine, and
552 Stool Specimens of COVID-19 Patients from the Republic of Korea. *Osong*
553 *Public Health Res Perspect* 2020, 11(3):112-117.
- 554 20. Rodríguez-Serrano DA, Roy-Vallejo E, Zurita Cruz ND, Martín Ramírez A,
555 Rodríguez-García SC, Arevalillo-Fernández N, Galván-Román JM, Fontán
556 García-Rodrigo L, Vega-Piris L, Chicot Llano M, Arribas Méndez D, González
557 de Marcos B, Hernando Santos J, Sánchez Azofra A, Ávalos Pérez-Urria E,
558 Rodríguez-Cortes P, Esparcia L, Marcos-Jimenez A, Sánchez-Alonso S, Llorente
559 I, Soriano J, Suárez Fernández C, García-Vicuña R, Ancochea J, Sanz J, Muñoz-
560 Calleja C, de la Cámara R, Canabal Berlanga A, González-Álvaro I, Cardeñoso
561 L; REINMUN-COVID Group: Detection of SARS-CoV-2 RNA in serum is
562 associated with increased mortality risk in hospitalized COVID-19 patients. *Sci*
563 *Rep* 2021, 23, 11(1):13134.
- 564 21. Hanson KE, Caliendo AM, Arias CA, Hayden MK, Englund JA, Lee MJ, Loeb
565 M, Patel R, El Alayli A, Altayar O, Patel P, Falck-Ytter Y, Lavergne V, Morgan
566 RL, Murad MH, Sultan S, Bhimraj A, Mustafa RA: Infectious Diseases Society
567 of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic
568 Testing. Infectious Diseases Society of America 2020, Version 2.0.0.
- 569

570 **TABLES**

571 **Table 1. Primers, linearity and melting curves parameters for SARS-CoV-2 and human RNase**
 572 **P amplification**

Target	Primers	Origin	Sequences	Amplicon size	Dinamic extension (Linearity)	PCR efficiency	Melting temperature
N	2019-nCoV_N2-F 2019-nCoV_N2-R	CDC-USA	5'-TTA CAA ACA TTG GCC GCA AA-3' 5'-GCG CGA CAT TCC GAA GAA-3'	67 bp	10 ⁶ – 10 ⁸ copies/μL	109.7%	80.8°C
RdRp	nCoV_IP4-14059Fw nCoV 1_IP4-14146Rv	Pasteur	5'-GGTAACTGGTATGATTTTCG-3' 5'-CTGGTCAAGGTTAATATAGG-3'	107 bp	10 ⁶ – 10 ⁸ copies/μL	105.4%	83.5°C
E	E_Sarbeco_F1 E_Sarbeco_R2	Charité	5'-ACAGGTACGTTAATAGTTAATA GCGT-3' 5'-ATATTGCAGCAGTACGCACACA-3'	113 bp	10 ⁶ – 10 ⁸ copies/μL	88.3%	77.6 °C
RNase P	RP-F RP-R	CDC-USA	5'-AGA TTT GGA CCT GCG AGC G-3' 5'-GAG CGG CTG TCT CCA CAA GT-3'	65 bp	10 ⁶ – 10 ⁸ copies/μL	95%	86°C

573

574

575 **Table 2. Precision of HRM-RTqPCR assays targeting SARS-CoV-2 E, N and RdRp.** SARS-CoV-2
 576 templates were assayed in 40 technical replicates, at 12, 10 and 8 copies/μL.

Parameter	Sample concentration		
	12 copies/μL	10 copies/μL	8 copies/μL
N target			
Positive samples, n=40	100%	100%	100%
Ct mean	29.80	30.44	30.57
Standard Deviation	0.5145	0.4274	0.5302
Coefficient of variation	1.726%	1.404%	1.735%
RdRp target			
Positive samples, n=40	97.5%	97.5%	97.5%
Ct mean	30.85	30.77	30.70
Standard Deviation	1.155	0.9851	0.8307
Coefficient of variation	3.743%	3.202%	2.706%
E target			
Positive samples, n=40	97.5%	87.5%	97.5%
Ct mean	28.87	28.41	28.70
Standard Deviation	0.4606	0.3599	1.046
Coefficient of variation	1.595%	1.267%	3.646%

577

578

579 **Table 3. Clinical validation of RT-qPCR assays targeting SARS-CoV-2 E, N and RdRp.** The
 580 parameters of clinical validation were calculated considering RT-qPCR with TaqMan assays as
 581 gold standard, using the OpenEpi (v. 3) software.

Parameters	HRM RTqPCR assays		
	N target [CI95%]	RdRp target [CI95%]	E target [CI95%]
Samples number	65	65	65
Sensitivity (%)	94.12 [84.08, 97.98]	98.04 [89.7-99.65]	92.16 [81.5-96.91]
Specificity (%)	100 [78.47, 100]	100 [78.47-100]	100 [78.47-100]
PPV (%)	100 [92.59, 100]	100 [92.86-100]	100 [92.44-100]
NPV (%)	82.35 [58.97, 93.81]	93.33 [70.18-98.81]	77.18 [54.78-91]
Diagnostic accuracy (%)	95.38 [87.29, 98.42]	98.46 [91.79-99.73]	93.85 [85.22-97.58]
Cohen's kappa coefficient	0.87 [0.63-1.11]	0.96 [0.71- 1.19]	0.84 [0.60- 1.08]

582 PPV: Positive predictive value, NPV: Negative predictive value, CI95%: 95% Confidence Intervals.

583

584 **FIGURE CAPTIONS**

585 **Figure 1. HRM-RTqPCR assays for SARS-CoV-2 E, N and RdRp targets. A.**

586 Derivative HRM curves for SARS-CoV-2 E (green), N (yellow) and RdRp (blue) and

587 Human RNase P (red) targets. The vertical blue lines divide the Pre-melt, Melt and Post-

588 melt regions. **B.** Normalized HRM curves for SARS-CoV-2 E (green), N (yellow) and

589 RdRp (blue) and Human RNase P (red) targets. **C.** Dinamic extension (linearity) for the

590 SARS-CoV-2 E (green), N (yellow) and RdRp (blue) targets amplification. **D.**

591 Normalized HRM curves for SARS-CoV-2 N region from COVID-19 clinical samples.

592 **E.** Normalized HRM curves for SARS-CoV-2 RdRp region from COVID-19 clinical

593 samples. **F.** Normalized HRM curves for SARS-CoV-2 E region from COVID-19 clinical

594 samples.

595

596 **Figure 2. Reproducibility of HRM-RTqPCR assays targeting SARS-CoV-2 E, N and**

597 **RdRp.** SARS-CoV-2 templates were assayed in 40 technical replicates, at 12, 10 and 8

598 copies/ μ L.

599

600 **Figure 3. Box-Plot of RNase P Ct values between RT-qPCR TaqMan and RT-qPCR**

601 **HRM assays and between swab, serum and saliva samples.** The Ct values from the

602 amplification of the internal control human RNase P was compared between TaqMan
 603 and HRM assays in all clinical specimens (A) or between swab, serum and saliva samples
 604 (B). The outliers are represented as the black circles. In A, $p=0.634$ (Mann-Whitney Rank
 605 Sum Test). In B, $*p<0.05$ (One-way ANOVA) and $p=1.00$ (Swab x Saliva - Mann-
 606 Whitney Rank Sum Test).

607
 608 **Figure 4. Bland-Altman Plots resulting from the pairwise comparison of Ct values**
 609 **between RT-qPCR TaqMan and HRM-RTqPCR assays targeting SARS-CoV-2 N,**
 610 **RdRp and E.** A. TaqMan N x HRM N targets. B. TaqMan N x HRM RdRp targets. C.
 611 TaqMan N x HRM E targets. Level of agreement between two assays, also known as
 612 observed mean difference (blue line at center), is presented as a function of the average
 613 Ct values of the two assays. Upper and lower limits of agreement (Upper and lower blue
 614 lines, respectively) defined by mean Ct difference ± 1.96 Standard Deviation (SD). The
 615 Bias observed were 0.56, -1.71 and -0.89 to A, B and C, respectively.

616
 617 **SUPPLEMENTARY TABLES**

618 **Table S1. Validation of the HRM-RTqPCR assays for SARS-CoV-2 E, N and RdRp targets.** Sixty-
 619 five RNA samples were extracted from nasopharyngeal swab, serum or saliva of patients
 620 suspicious for Covid-19. All samples were analyzed for RT-qPCR TaqMan assays targeting SARS-
 621 CoV-2 N2 and Human RNaseP targets, in parallel to the HRM-RTqPCR assays.

#	Sa mp le	TaqMan RNase P target			TaqMan N target			HRM N target			HRM RdRp target			HRM E target			HRM Rnase P target		
		Res ult	CT M ea n	Ct S D	Res ult	CT Me an	Ct SD	Res ult	CT M ea n	Ct S D	Res ult	CT M ea n	Ct S D	Res ult	CT M ea n	Ct S D	Res ult	CT M ea n	Ct S D
1	Sw ab	Pos itiv e	22. 53 2	0. 00 1	Posi tive	36. 36 0	0. 64 0	Posi tive	34. 04 6	0. 29 5	Posi tive	29. 55 6	0. 13 3	Posi tive	29. 90 7	1. 80 9	ND	-	-
2	Sw ab	Pos itiv e	27. 51 1	0. 08 7	Posi tive	34. 97 4	0. 44 2	Posi tive	36. 24 3	2. 72 2	Posi tive	34. 06 5	1. 97 8	Posi tive	32. 05 7	1. 95 3	ND	-	-
3	Sw ab	Pos itiv e	26. 88 7	0. 18 9	Posi tive	25. 44 8	0. 12 8	Posi tive	25. 71 4	0. 44 5	Posi tive	32. 56 4	0. 61 0	Posi tive	31. 30 2	1. 51 6	ND	-	-
4	Sw ab	Pos itiv e	26. 40 3	0. 10 7	Posi tive	29. 11 3	0. 01 6	Posi tive	27. 65 6	0. 13 5	Posi tive	27. 97 8	0. 56 8	Posi tive	34. 61 1	5. 01 5	ND	-	-

5	Sw ab	Pos itive	25. 48 5	0. 00 4	Posi tive	33. 78 4	1. 06 2	Posi tive	33. 78 0	1. 19 3	Posi tive	30. 51 0	0. 36 2	Posi tive	29. 90 9	1. 85 5	ND	-	-
6	Sw ab	Pos itive	23. 84 5	0. 00 0	Posi tive	32. 57 6	0. 38 5	Posi tive	26. 52 3	0. 17 2	Posi tive	27. 31 1	0. 51 8	Posi tive	33. 13 5	1. 80 3	ND	-	-
7	Sw ab	Pos itive	25. 60 3	0. 02 0	Posi tive	31. 67 5	6. 02 0	Posi tive	30. 38 9	0. 04 9	Posi tive	16. 34 0	0. 41 7	Posi tive	17. 74 5	0. 40 9	ND	-	-
8	Sw ab	Pos itive	24. 27 1	0. 07 2	Posi tive	29. 56 3	0. 21 3	Posi tive	31. 24 6	0. 22 7	Posi tive	22. 31 9	0. 04 8	Posi tive	22. 53 5	0. 07 1	ND	-	-
9	Sw ab	Pos itive	24. 85 7	0. 00 8	Posi tive	22. 85 2	0. 03 3	Posi tive	24. 75 2	0. 00 4	Posi tive	24. 46 3	0. 10 1	Posi tive	30. 87 2	0. 22 5	ND	-	-
10	Sw ab	Pos itive	23. 91 9	0. 12 0	Posi tive	33. 23 9	0. 51 0	Posi tive	32. 97 4	1. 15 6	Posi tive	24. 26 2	0. 56 1	Posi tive	24. 13 7	0. 45 4	ND	-	-
11	Sw ab	Pos itive	24. 89 4	0. 05 2	Posi tive	26. 73 4	0. 23 2	Posi tive	26. 91 1	0. 30 4	Posi tive	23. 78 5	0. 01 4	Posi tive	24. 56 6	0. 21 7	Pos itive	23. 70 1	0. 16 6
12	Sw ab	Pos itive	27. 72 6	0. 10 5	Posi tive	27. 74 4	0. 21 5	Posi tive	29. 33 3	0. 09 2	Posi tive	24. 17 2	0. 34 3	Posi tive	24. 86 3	0. 05 9	Pos itive	27. 67 7	0. 14 3
13	Sw ab	Pos itive	28. 67 4	0. 29 0	Posi tive	25. 78 6	0. 22 7	Posi tive	26. 14 9	0. 25 9	Posi tive	24. 02 2	0. 20 3	Posi tive	24. 84 0	0. 17 9	Pos itive	27. 92 6	0. 03 8
14	Sw ab	Pos itive	25. 63 0	0. 08 0	Posi tive	26. 22 7	0. 59 5	Posi tive	24. 95 9	0. 26 6	Posi tive	23. 91 2	0. 04 1	Posi tive	24. 80 0	0. 08 0	Pos itive	24. 61 2	0. 14 9
15	Sw ab	Pos itive	25. 53 8	0. 08 5	Posi tive	28. 58 6	- - -	Posi tive	27. 05 1	0. 35 2	Posi tive	27. 94 3	0. 72 9	Posi tive	28. 55 5	0. 63 3	Pos itive	24. 40 4	0. 02 4
16	Sw ab	Pos itive	30. 98 6	- - -	Posi tive	24. 25 5	0. 00 9	Posi tive	26. 00 2	0. 81 3	Posi tive	23. 23 5	0. 07 7	Posi tive	23. 66 5	0. 09 7	Pos itive	30. 97 2	0. 20 9
17	Sw ab	Pos itive	30. 35 8	0. 97 2	Posi tive	25. 10 9	0. 06 1	Posi tive	28. 16 1	0. 41 5	Posi tive	23. 65 0	0. 18 3	Posi tive	24. 91 7	0. 34 7	Pos itive	29. 34 8	0. 49 3
18	Sw ab	Pos itive	29. 50 2	- - -	Posi tive	20. 10 1	0. 08 1	Posi tive	20. 56 1	0. 20 2	Posi tive	21. 95 6	0. 49 7	Posi tive	23. 46 3	1. 98 7	Pos itive	29. 68 7	0. 07 3
19	Sw ab	Pos itive	30. 78 0	0. 18 8	Posi tive	27. 62 8	- - -	Posi tive	14. 83 5	0. 70 1	Posi tive	27. 41 7	0. 31 3	Posi tive	28. 85 3	0. 74 8	Pos itive	31. 39 3	- - -
20	Sw ab	Pos itive	25. 13 2	0. 03 4	Posi tive	17. 48 3	0. 70 3	Posi tive	30. 16 3	0. 79 7	Posi tive	15. 31 0	0. 09 0	Posi tive	16. 20 9	0. 09 2	Pos itive	24. 25 4	0. 02 8
21	Sw ab	Pos itive	27. 58 5	0. 07 5	Posi tive	26. 45 4	0. 08 7	Posi tive	28. 62 7	0. 13 3	Posi tive	25. 26 9	0. 03 2	Posi tive	25. 62 9	0. 17 7	Pos itive	27. 75 8	0. 30 4
22	Sw ab	Pos itive	27. 70 0	0. 01 2	Posi tive	27. 04 6	0. 19 5	Posi tive	29. 27 1	0. 18 5	Posi tive	25. 95 9	0. 00 3	Posi tive	26. 64 6	0. 43 0	Pos itive	27. 96 5	0. 43 1
23	Sw ab	Pos itive	26. 40 4	0. 09 5	Posi tive	23. 72 7	0. 24 3	Posi tive	22. 66 1	0. 21 7	Posi tive	22. 28 1	0. 05 5	Posi tive	23. 26 8	0. 14 5	Pos itive	25. 55 4	0. 13 8
24	Sw ab	Pos itive	29. 62 3	0. 05 0	Posi tive	29. 12 4	0. 26 6	Posi tive	29. 59 1	0. 00 9	Posi tive	28. 68 3	0. 11 3	Posi tive	29. 06 7	0. 33 7	Pos itive	29. 76 9	0. 13 7
25	Sw ab	Pos itive	28. 55 0	0. 00 3	Posi tive	29. 65 3	0. 33 6	Posi tive	30. 11 0	0. 60 3	Posi tive	28. 10 5	0. 40 6	Posi tive	28. 98 4	0. 37 2	Pos itive	28. 40 6	0. 07 4
26	Sw ab	Pos itive	27. 74 9	0. 04 2	Posi tive	21. 30 6	0. 06 5	Posi tive	21. 49 4	0. 16 0	Posi tive	18. 93 0	0. 12 0	Posi tive	20. 68 7	0. 12 2	Pos itive	27. 58 2	0. 01 6
27	Sw ab	Pos itive	26. 43 5	0. 02 1	Posi tive	22. 30 0	0. 01 4	Posi tive	21. 08 9	0. 27 4	Posi tive	20. 12 5	0. 34 9	Posi tive	20. 67 2	0. 08 3	Pos itive	26. 23 3	0. 77 3

28	Sw	Pos	27.06	0.08	Positive	27.67	0.31	Positive	27.58	0.22	Positive	26.13	0.51	Positive	26.78	0.64	Positive	27.11	0.34
29	Sw	Pos	28.10	0.60	Positive	20.08	0.12	Positive	19.43	0.27	Positive	18.00	0.32	Positive	18.98	0.30	Positive	27.00	0.32
30	Sw	Pos	27.64	0.09	Positive	21.60	0.04	Positive	21.69	0.04	Positive	19.33	0.00	Positive	20.43	0.10	Positive	28.09	0.80
31	Sw	Pos	25.41	0.04	Positive	32.71	0.50	Positive	34.89	0.99	Positive	31.09	0.41	Positive	31.85	1.90	Positive	25.38	0.33
32	Sw	Pos	20.49	0.03	Positive	14.59	0.01	Positive	14.18	0.48	Positive	18.74	1.87	Positive	15.47	0.38	Positive	21.81	0.45
33	Sw	Pos	26.16	0.00	Positive	36.12	0.01	Negative	-	-	Positive	33.85	1.78	Negative	-	-	Positive	26.43	0.62
34	Sw	Pos	25.72	0.00	Positive	34.49	1.35	Negative	-	-	Positive	24.66	2.55	Negative	-	-	Positive	25.65	0.26
35	Sw	Pos	26.37	0.05	Positive	34.31	1.25	Positive	34.62	0.95	Positive	35.11	1.98	Negative	-	-	Positive	26.19	0.02
36	Sw	Pos	21.86	0.25	Positive	13.15	0.02	Positive	15.82	0.04	Positive	12.63	0.92	Positive	12.76	1.61	Positive	21.85	0.48
37	Sw	Pos	22.55	0.00	Positive	18.98	0.02	Positive	20.13	0.17	Positive	17.76	0.41	Positive	18.38	0.27	Positive	26.77	0.06
38	Sw	Pos	25.28	0.11	Positive	35.55	2.26	Positive	34.94	0.25	Positive	33.02	0.34	Positive	32.12	-	Positive	26.26	0.75
39	Sw	Pos	25.98	0.07	Positive	30.55	0.00	Positive	32.60	0.88	Positive	29.19	0.23	Positive	31.15	0.82	Positive	26.40	0.17
40	Sw	Pos	25.21	0.02	Positive	31.32	0.04	Positive	34.82	0.48	Positive	32.89	0.74	Positive	31.90	0.44	Positive	25.25	0.04
41	Sw	Pos	21.47	0.08	Positive	18.11	0.04	Positive	20.52	0.09	Positive	14.89	0.16	Positive	16.61	1.90	Positive	21.16	0.05
42	Sw	Pos	24.26	0.04	Negative	-	-	Negative	-	-	Negative	-	-	Negative	-	-	Positive	24.38	0.19
43	Ser	Pos	28.14	0.08	Positive	31.70	0.24	Positive	31.84	0.20	Positive	31.17	0.03	Positive	31.47	0.95	Positive	28.36	0.87
44	Ser	Pos	34.89	0.35	Negative	-	-	Negative	-	-	Negative	-	-	Negative	-	-	ND	-	-
45	Ser	Pos	31.86	0.49	Negative	-	-	Negative	-	-	Negative	-	-	Negative	-	-	Positive	30.63	0.56
46	Ser	Pos	28.84	0.00	Negative	-	-	Negative	-	-	Negative	-	-	Negative	-	-	Positive	28.95	0.03
47	Ser	Pos	29.81	0.33	Negative	-	-	Negative	-	-	Negative	-	-	Negative	-	-	Positive	30.31	0.00
48	Ser	Pos	31.68	0.01	Negative	-	-	Negative	-	-	Negative	-	-	Negative	-	-	Positive	31.64	0.01
49	Ser	Pos	29.69	0.46	Negative	-	-	Negative	-	-	Negative	-	-	Negative	-	-	Positive	29.49	0.26
50	Ser	Pos	33.03	0.00	Negative	-	-	Negative	-	-	Negative	-	-	Negative	-	-	Positive	31.82	0.02

5	Ser	Pos	28.	0.	Neg	-	-	Neg	-	-	Neg	-	-	Neg	-	-	Pos	27.	0.
1	um	itiv	14	02	ativ	-	-	ativ	-	-	ativ	-	-	ativ	-	-	itiv	80	49
		e	6	8	e			e			e			e			e	1	9
5	Ser	Pos	27.	0.	Neg	-	-	Neg	-	-	Neg	-	-	Neg	-	-	Pos	27.	0.
2	um	itiv	84	17	ativ	-	-	ativ	-	-	ativ	-	-	ativ	-	-	itiv	91	32
		e	1	9	e			e			e			e			e	4	0
5	Ser	Pos	25.	0.	Posi	37.	0.	Neg	-	-	Neg	-	-	Neg	-	-	Pos	33.	
3	um	itiv	79	18	tive	02	06	ativ	-	-	ativ	-	-	ativ	-	-	itiv	78	
		e	1	6	e	1	7	e			e			e			e	1	
5	Ser	Pos	31.	0.	Neg	-	-	Neg	-	-	Neg	-	-	Neg	-	-	Pos	35.	5.
4	um	itiv	32	44	ativ	-	-	ativ	-	-	ativ	-	-	ativ	-	-	itiv	20	31
		e	7	1	e			e			e			e			e	3	9
5	Sali	Pos	40.		Neg	-	-	Neg	-	-	Neg	-	-	Neg	-	-	Pos	30.	2.
5	va	itiv	48		ativ	-	-	ativ	-	-	ativ	-	-	ativ	-	-	itiv	04	95
		e	1		e			e			e			e			e	3	7
5	Sali	Pos	29.	0.	Posi	24.	0.	Posi	27.	1.	Posi	24.	0.	Posi	24.	0.	Pos	25.	0.
6	va	itiv	58	08	tive	87	06	tive	40	25	tive	10	27	tive	71	32	itiv	30	06
		e	5	6	e	8	3	e	2	2	e	3	3	e	5	8	e	7	3
5	Sali	Pos	27.	0.	Posi	15.	0.	Posi	16.	0.	Posi	14.	0.	Posi	15.	0.	Pos	15.	0.
7	va	itiv	63	33	tive	40	13	tive	99	68	tive	60	93	tive	15	23	itiv	15	23
		e	5	2	e	3	8	e	1	8	e	7	3	e	7	0	e	7	0
5	Sali	Pos	31.	0.	Posi	29.	0.	Posi	29.	0.	Posi	28.	0.	Posi	28.	1.	Pos	28.	1.
8	va	itiv	12	30	tive	67	30	tive	75	05	tive	95	46	tive	72	34	itiv	72	34
		e	0	9	e	0	8	e	2	3	e	1	3	e	2	6	e	2	6
5	Sali	Pos	31.	0.	Posi	23.	0.	Posi	24.	0.	Posi	21.	0.	Posi	22.	0.	Pos	24.	1.
9	va	itiv	87	29	tive	13	24	tive	50	16	tive	73	01	tive	27	74	itiv	40	99
		e	4	0	e	0	4	e	8	1	e	1	8	e	6	5	e	0	1
6	Sali	Pos	29.	0.	Posi	26.	0.	Posi	27.	0.	Posi	25.	0.	Posi	26.	0.	Pos	26.	1.
0	va	itiv	05	11	tive	94	00	tive	58	17	tive	99	57	tive	48	52	itiv	19	58
		e	2	8	e	3	9	e	3	5	e	7	6	e	4	3	e	2	0
6	Sali	Pos	29.	0.	Neg	-	-	Neg	-	-	Neg	-	-	Neg	-	-	Pos	28.	4.
1	va	itiv	44	18	ativ	-	-	ativ	-	-	ativ	-	-	ativ	-	-	itiv	52	73
		e	2	4	e			e			e			e			e	9	0
6	Sali	Pos	20.	0.	Posi	15.	0.	Posi	16.	0.	Posi	16.	0.	Posi	15.	0.	Pos	15.	0.
2	va	itiv	61	09	tive	06	47	tive	16	59	tive	03	32	tive	40	23	itiv	40	23
		e	9	0	e	5	7	e	5	6	e	7	8	e	9	1	e	9	1
6	Sali	Pos	22.	0.	Posi	27.	0.	Posi	29.	0.	Posi	24.	2.	Posi	27.	1.	Pos	28.	0.
3	va	itiv	80	16	tive	40	07	tive	48	27	tive	73	41	tive	68	01	itiv	00	22
		e	8	7	e	7	8	e	4	9	e	0	0	e	0	1	e	5	4
6	Sali	Pos	21.	0.	Posi	23.	0.	Posi	26.	0.	Posi	24.	0.	Posi	24.	0.	Pos	24.	0.
4	va	itiv	26	03	tive	24	17	tive	25	10	tive	97	87	tive	52	13	itiv	52	13
		e	9	7	e	7	6	e	0	9	e	8	9	e	6	1	e	6	1
6	Sali	Pos	30.	0.	Neg	-	-	Neg	-	-	Neg	-	-	Neg	-	-	Pos	36.	4.
5	va	itiv	84	39	ativ	-	-	ativ	-	-	ativ	-	-	ativ	-	-	itiv	44	02
		e	3	1	e			e			e			e			e	0	7

622 ND: Not done. Ct: Threshold cycle. SD: Standard Deviation.

623







